[Characteristics of private and irregular prescription for oral antibiotics in Spanish community pharmacies]. / Perfil de las solicitudes de antibióticos en farmacia comunitaria con receta privada y prescripción irregular.

OBJECTIVE: To quantify the proportion of oral antibiotics through private prescription (PP) and irregular prescription (IP) in the Community Pharmacy (CP). MATERIAL AND METHODS: Cross-sectional multicentre study carried out in Spanish community pharmacies over a 4week period, one in each season of the year. An analysis was made of private and irregular prescriptions of oral J01 antibacterials for systemic use (Anatomical Therapeutic Chemical [ATC] classification). The study variables used were prescription and consultation characteristics. RESULTS: A total of 3569 PP (71% followed legislation) and 833 IP were recorded by 365 pharmacists working in 247 CP. PP were prescribed by dentists (43.7%), general practitioners (GP) (26.20%), and paediatricians (10.3%), to treat teeth infections (39.8%), upper respiratory infections (25.6%), lower respiratory infections (10.3%), and urinary infections (7.7%). The most prescribed antibiotics were amoxicillin (27.9%) and amoxicillin-clavulanic (25.2%). IP came from Emergency Departments (32.8%), oral/phone prescriptions (20.4%), and patient demand due to insufficient quantity of antibiotic to complete treatment (10%). Prescriptions came from GP (25.2%), dentists (24.7%), and paediatricians (12%) to treat upper respiratory infections (32.5%), teeth infections (25.8%), urinary infections (14.2%), and lower respiratory infections (10.8%). The most prescribed antibiotics were amoxicillin-clavulanic (27.4%) and amoxicillin (21.6%). Since every patient with IP was referred to the GP, 45.4% of them accepted the recommendations of the pharmacists. CONCLUSIONS: This study obtained PP and IP characteristics, unknown and needed data in Spain for future health policy plans.

Patrones de prescripción de metadona entre médicos colombianos especialistas en manejo del dolor / Methadone Prescription Patterns among Pain Physicians in Colombia

Introducción: el dolor crónico es una enfermedad con graves consecuencias para personas, médicos y sistemas de salud. Una de las estrategias de manejo es el uso prolongado de opioides, y dentro de los disponibles en Colombia se encuentra la metadona, con características farmacológicas únicas y asociación con aumento de mortalidad por sobredosis y complicaciones cardiovasculares. La adecuada prescripción y seguimiento de metadona se relaciona con complicaciones similares al manejo con otros opioides. Objetivo: describir los patrones de prescripción de metadona entre médicos colombianos especialistas en manejo de dolor y comparar estos patrones de prescripción con las recomendaciones mayormente aceptadas por la comunidad científica internacional. Materiales y métodos: se utilizó una encuesta electrónica estructurada aplicada entre médicos especialistas en dolor identificados a través de las principales agremiaciones y programas de formación nacionales. Resultados: los encuestados que respondieron son mayoritariamente experimentados anestesiólogos, con entrenamiento universitario clínico y que trabajan en hospitales universitarios. La mayoría de ellos percibe como efectivo el manejo a largo plazo con opioides para el control analgésico y la mejoría funcional, a pesar de la falta de respaldo empírico. La mayoría no aplica las herramientas recomendadas por guías de práctica clínica, aunque las conocen. Conclusiones: se debe mejorar la educación de prescriptores de metadona para mejorar la seguridad de los pacientes. Se infiere pobre aplicabilidad de herramientas recomendadas por guías de práctica clínica en el medio colombiano. Los resultados de la presente encuesta no son fácilmente generalizables.

Background: Chronic pain is a disease with serious consequences for people, physicians, and health care systems. Chronic opioid usage is one of this therapy strategy. Methadone is among the available opioids in Colombia and it is characterized by unique pharmacological properties and increased mortality reports because of overdose and cardiovascular complications. Appropriate monitoring and prescribing patterns of methadone are associated with complications similar to chronic management with other opioids. Aim: To describe methadone prescribing patterns among Colombian pain physicians and compare them to the accepted recommendations by the international scientific community. Materials and Methods: An electronic structured survey was applied to pain specialist physicians identified through major pain study associations and national training programs. Results: Respondents of the survey are mostly experienced university certified physicians and anesthesiologists with clinical training working at university hospitals. Most of them perceive chronic opioid therapy as an effective strategy for pain relief and functional outcomes despite the lack of empirical support. Most of them know clinical practice guidelines but are not applying them despite this matter. Conclusions: We must enhance education for prescribers in order to improve patient safety. The recommended clinical practice guidelines are poorly applied by Colombian doctors. The results of this study must be cautiously assessed.

[Co-payment on prescription drugs in the Spanish public health system: Certainty, risk and selection of risks]. / Copago en farmacia de receta en la sanidad pública española: certezas, riesgos y selección de riesgos.

The model of co-payment on prescription drugs in the Spanish National Health System (NHS) changed on 1 July 2012. For more than three decades that it was not modified. This article provides a brief historical reminder of the evolution of this model of co-payment. The basic characteristics of this model are compared with the model of copayment on prescription drugs of the Administrative Mutualism (Civil Servants). The document provides detailed information on the percentage of effective copayment, fundraising effects, the economic participation of the patient, among others, in both models. Finally, listed pending improvements not addressed by 2012 changes such as the concentration of the co-payment in the active patient population and risk selection promoted by the differences in the financial contribution between the two models of co-payment (NHS and Mutualist).

Mercado farmacéutico en México: tamaño, valor y concentración / The pharmaceutical market in Mexico: size, value, and concentration

OBJETIVO: Caracterizar el mercado de medicamentos de México en cuanto a su tamaño, organización, poder de mercado de las empresas y capacidad de negociación de los consumidores. MÉTODOS: Estudio descriptivo a partir de los datos de los Censos Económicos de 2004 y los informes de Intercontinental Marketing Services. Se obtuvieron los montos y volúmenes de ventas de las empresas del sector farmacéutico mexicano de 2002 a 2005 y se calcularon el índice de Herfindahl-Hirschman (IHH) y su inverso como indicadores del grado de concentración del mercado, así como la elasticidad del precio por un producto índice. RESULTADOS: El valor total de los productos elaborados por el sector farmacéutico fue de 115 mil millones en pesos de 2006, de los que 99,0 por ciento correspondió a las empresas clasificadas como grandes. Este monto representó 1,2 por ciento del producto interno bruto nacional de ese año (20,0 por ciento de la participación del sector salud, estimada en 6,0 por ciento) y 3,9 por ciento del valor de los productos de manufactura. El IHH del mercado farmacéutico mexicano en el período analizado fue de alrededor de 0,04, aunque con una reducción sostenida, y su inverso se redujo de 23 a 26. La elasticidad del precio de los productos farmacéuticos entre 2003 y 2005 fue mínima (0,007, 0,003 y -0,002). CONCLUSIONES: Este trabajo constituye una primera caracterización del mercado farmacéutico mexicano, uno de los sectores más dinámicos de la economía nacional. Se comprobó que se trata de un mercado oligopólico e inelástico, por lo que se justifica la creación de mecanismos regulatorios más sólidos que reduzcan el poder de los productores en favor de los consumidores.

OBJECTIVES: To describe the pharmaceutical drug market in Mexico in terms of its size, structure, business' market power, and consumer negotiating power. METHODS: A descriptive study based on data from the 2004 Economics Census and the reports of IMS Health, Inc. (Norwalk, Connecticut, United States of America). Sales amounts and volumes of Mexico's pharmaceutical companies from 2002-2005 were obtained and the Herfindahl-Hirschman Index (HHI) and its inverse were calculated as indicators of the market's degree of concentration; also, price elasticity was determined by a product index. RESULTS: The total value of the products manufactured by the pharmaceutical sector was 115 billion in 2006 Mexican pesos, of which 99 percent pertained to companies categorized as large. This amount constituted 1.2 percent of the national gross domestic product that year (20.0 percent of the health sector's portion, estimated to be 6.0 percent) and 3.9 percent of the total value of manufactured goods. The HHI of Mexico's pharmaceutical market during the study period was about 0.04, albeit with a steady decline, and its inverse decreased from 23 to 26. The price elasticity of pharmaceutical products was minimal (0.007, 0.003, and -0.002). CONCLUSIONS: This study constitutes a preliminary description of Mexico's pharmaceutical market, one of the country's most dynamic economic sectors. It confirmed that the market is a rigid oligopoly, and thus supports enactment of firmer regulatory tools to reduce the power of the manufacturers in favor of that of the consumers.

Erros na prescrição hospitalar de medicamentos potencialmente perigosos / Errors in hospital prescriptions of high-alert medications

OBJETIVO:Os erros de medicação são atualmente um problema mundial de saúde pública, sendo os mais sérios os de prescrição. O objetivo do estudo foi analisar a prática da prescrição de medicamentos de alto risco e sua relação com a prevalência de erros de medicação em ambiente hospitalar. MÉTODOS:Estudo transversal retrospectivo abrangendo 4.026 prescrições com medicamentos potencialmente perigosos. Durante 30 dias de 2001, foram analisadas todas as prescrições recebidas na farmácia de um hospital de referência de Minas Gerais. As prescrições foram analisadas quanto a: legibilidade, nome do paciente, tipo de prescrição, data, caligrafia ou grafia, identificação do prescritor, análise do medicamento e uso de abreviaturas. Os erros de prescrição foram classificados como de redação ou decisão, sendo avaliada a influência do tipo de prescrição na ocorrência de erros. RESULTADOS: Houve predomínio da prescrição escrita à mão (45,7%). Em 47,0% das prescrições escritas à mão, mistas e pré-digitadas ocorreram erros no nome do paciente, em 33,7% houve dificuldades na identificação do prescritor e 19,% estavam pouco legíveis ou ilegíveis. No total de 7.148 medicamentos de alto risco prescritos, foram observados 3.177 erros, sendo mais freqüente a omissão de informação (86,5%). Os erros se concentraram principalmente nos medicamentos heparina, fentanil e midazolam; e os setores de tratamento intensivo e a neurologia apresentaram maior número de erros por prescrição. Observou-se o uso intensivo e sem padronização de abreviaturas. Quando computados todos os tipos de erros, verificou-se 3,3 por prescrição. A prescrição pré-digitada apresentou menor chance de erros do que as mistas ou escritas à mão. CONCLUSÕES: Os resultados sugerem a necessidade da padronização no processo de prescrição e a eliminação daquelas feitas à mão. O uso de prescrições pré-digitadas ou editadas poderá diminuir os erros relacionados...

OBJECTIVE:Medication errors are currently a worldwide public health issue and it is one of the most serious prescription errors. The objective of the study was to evaluate the practice of prescribing high-alert medications and its association with the prevalence of medication errors in hospital settings. METHODS: A retrospective cross-sectional study was conducted including 4,026 prescription order forms of high-alert medications. There were evaluated all prescriptions received at the pharmacy of a reference hospital in the state of Minas Gerais, southeastern Brazil, over a 30-day period in 2001. Prescription were checked for legibility, patient name, type of prescription, date, handwriting or writing, prescriber identification, drug prescribed, and use of abbreviations. Prescription errors were classified as writing or decision errors and how the type of prescription affected the occurrence of errors was assessed. RESULTS: Most prescriptions were handwritten (45.7%). In 47.0% of handwritten, mixed and pre-typed prescriptions had patient name errors; the prescriber name was difficult to identify in 33.7%; 19.3% of them were hardly legible or illegible. Of a total of 7,148 high-alert drugs prescribed, 3,177 errors were found, and the most frequent one was missing information (86.5%). Errors occurred mostly in prescriptions of heparin, phentanyl, and midazolam. Intensive care and neurology units had the highest number of errors per prescription. Non-standard abbreviations were frequent and widespread. Overall it was estimated 3.3 errors per prescription order form. Pre-typed prescriptions were less likely to have errors compared to mixed or handwritten prescriptions. CONCLUSIONS: The study results show there is a need for standardizing the prescription process and eliminating handwritten prescriptions. The use of pre-typed or edited prescriptions may reduce errors associated to high-alert medications.

OBJETIVO:Los errores de medicación son actualmente un problema mundial de salud pública, siendo los más serios los de prescripción. El objetivo del estudio fue analizar la práctica de la prescripción de medicamentos de alto riesgo y su relación con la prevalencia de errores de medicación en ambiente hospitalario. MÉTODOS: Estudio transversal retrospectivo abarcando 4.026 prescripciones con medicamentos potencialmente peligrosos. Durante 30 días de 2001, fueron analizadas todas las prescripciones recibidas en la farmacia de un hospital de referencia del estado de Minas Gerais (Sureste de Brasil). Las prescripciones fueron analizadas con relación a: legibilidad, nombre del paciente, tipo de prescripción, fecha, caligrafía o grafía, identificación del prescriptor, análisis del medicamento y uso de abreviaturas. Los errores de prescripción fueron clasificados como de redacción o decisión, siendo evaluada la influencia del tipo de prescripción en la ocurrencia de errores. RESULTADOS: Hubo predominio de la prescripción escrita a mano (45,7%). En 47,0% de las prescripciones escritas a mano, mixtas y pre-digitadas ocurrieron errores en el nombre del paciente, en 33,7% hubo dificultades en la identificación del prescriptor y 19,3% estaban poco legibles o ilegibles. En un total de 7.148 medicamentos de alto riesgo prescritos, fueron observados 3.177 errores, siendo más frecuente la omisión de información (86,5%). Los errores se concentraron principalmente en los medicamentos heparina, fentanil y midazolam; y los sectores de tratamiento intensivo y la neurología presentaron mayor número de errores por prescripción. Se observó el uso intensivo y sin estandarización de abreviaturas. Cuando se computaron todos los tipos de errores, se verificó 3,3 por prescripción. La prescripción pre-digitada presentó menor probabilidad de errores en comparación con las mixtas o escritas a mano. CONCLUSIONES:Los resultados...